Antibiotics: A Global Strategic Business Report
San Jose, CA (PRWEB) July 25, 2007
Long-term growth in the global antibiotics market is expected to be primarily impacted by two key factors - antibiotic resistance and generic competition. Antibiotic resistance, which compels reduction in the usage of antibiotics, represents the primary market inhibitor. In recent times, there has been a decline in antibiotic prescriptions for respiratory related infections. Another factor that could have a strong bearing on the market over the next five to seven years is the rising generic competition. Market for antibacterial drugs is forecast to experience restricted growth as a result of patent expiries of antibiotic products from various companies such as Abbott, AstraZeneca, Daiichi-Sankyo, Johnson & Johnson, Merck, and Wyeth.
United States represents the largest market, with revenues estimated to be US$8.4 billion in 2007, as stated by Global Industry Analysts, Inc. Europe represents the second largest market, with US$6.3 billion. Asia Pacific represents the potential market, projected to register a CAGR of 4.81%.
In terms of product segments, Cephalosporin represents the largest, estimated to generate US$6.8 billion in 2007. The segment is forecast to experience a negative CAGR of 2% over the next five years. Generic competition and increased resistance continue to plague this mature market. Penicillin, Quinolones, Macrolides and Carbapenems represent other major segments in the global antibiotics market. Facing problems similar to Cephalosporin, Penicillin market is expected to experience negative CAGR and decline to US$3.5 billion by 2010. However, Carbapenems represents the lone high-growth segment among the key drug classes, with a CAGR of 8% over the next five years.
New classes of drugs entering the market are offsetting lackluster growth in major antibiotic drug classes. A variety of new drugs with improved effectiveness and reduced resistance have already entered the market and many are in the pipeline. Bright spots in an otherwise lackluster antibiotics market include glycopeptides (Vancomycin, Teicoplanin) and Oxazolidinones (Pfizer's Zyvox). These and other drug classes included under the others category in the report represents the fastest growing segment, with a robust CAGR of 12% over the next five years.
Leading players in the worldwide antibiotics market include GlaxoSmithKline, Pfizer Inc., Johnson & Johnson, Bristol-Myers Squibb, Roche, Advancis Pharmaceutical Corp., Bayer HealthCare AG, Cubist Pharmaceuticals, Inc., Daiichi Sankyo Company Limited, Eli Lilly and Co., Kyorin Pharmaceutical Co., Ltd., LG Life Sciences Limited, Novartis AG, Pliva d.d., Ranbaxy Laboratories Ltd, Sanofi-Aventis SA, Toyama Chemical Co., Ltd., and Wyeth Pharmaceuticals, Inc.
The report titled "Antibiotics: A Global Strategic Business Report" published by Global Industry Analysts, Inc., presents detailed analyses and coverage of the US, Canadian, Japanese, European (including French, German, Italian, UK, Spanish, and Rest of Europe), Asia-Pacific, and Rest of World markets. The report takes a hard look at generic competition and forthcoming product developments that would shape the future of the global antibiotics market.
For more details about this research report, please visit http://www.strategyr.com/MCP-1705.asp.
About Global Industry Analysts, Inc.
Global Industry Analysts, Inc., (GIA) is a reputed publisher of off-the-shelf market research. Founded in 1987, the company is globally recognized as one of the world's largest market research publishers. The company employs more than 700 people worldwide and publishes more than 880 full-scale research reports each year. Additionally, the company also offers a range of more than 60,000 smaller research products including company reports, market trend reports and industry reports encompassing all major industries worldwide.
Global Industry Analysts, Inc.
Web Site http://www.StrategyR.com